US Stock MarketDetailed Quotes
SPRO Spero Therapeutics
- 1.430
- +0.010+0.70%
Close Apr 25 16:00 ET
- 1.450
- +0.020+1.40%
Pre 07:35 ET
77.07MMarket Cap3.33P/E (TTM)
1.460High1.388Low175.45KVolume1.420Open1.420Pre Close250.52KTurnover0.44%Turnover Ratio3.33P/E (Static)53.89MShares1.99552wk High0.72P/B56.94MFloat Cap0.99052wk Low--Dividend TTM39.82MShs Float23.639Historical High--Div YieldTTM5.07%Amplitude0.680Historical Low1.427Avg Price1Lot Size
About Spero Therapeutics Company
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.
Company Profile
SymbolSPRO
Company NameSpero Therapeutics
Listing DateNov 2, 2017
Issue Price14.00
Founded2013
CEOMr. Satyavrat Shukla, C.F.A.
MarketNASDAQ
Employees46
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address675 Massachusetts Avenue,14th floor
CityCambridge
ProvinceMassachusetts
CountryUnited States of America
Zip Code02139
Phone1-857-242-1600
Company Executives
- Name
- Position
- Salary
- Satyavrat Shukla, C.F.A.
- Director, President and Chief Executive Officer
- 2.02M
- Timothy Keutzer
- Chief Development Officer and Chief Operating Officer
- 1.44M
- Kamal Hamed
- Chief Medical Officer
- --
- Esther Rajavelu
- Chief Financial Officer, Treasurer and Chief Business Officer
- --
- Dr. Ankit Mahadevia, M.D.
- Chairman of the Board
- 2.39M
- Frank E. Thomas
- Independent Director
- 88.83K
- Dr. Patrick V.J.J. Vink, M.D.
- Lead Independent Director
- 93.19K
- Dr. John C. Pottage,Jr,M.D.
- Independent Director
- 83.20K
- Kathleen Tregoning
- Independent Director
- 73.17K
- Scott T. Jackson, M.B.A.
- Independent Director
- 80.70K
- Dr. Milind S. Deshpande, PhD
- Independent Director
- 105.70K
- Cynthia Smith
- Independent Director
- 73.20K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg